Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN10A | Q9Y5Y9 | 6/20 | 0.62 |
| ▸ | SCN2A | Q99250 | 5/20 | 0.62 |
| ▸ | KDM1A | O60341 | 3/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.44 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | HPGDS | O60760 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23327910 | 0.91 | SCN10A (0.75) | SCN10ASCN2AKDM1AHDAC1MCHR1 | |
| SCHEMBL23344685 | 0.89 | SCN10A (0.60) | SCN10ASCN2AKDM1AHDAC1MCHR1 | |
| SCHEMBL23327907 | 0.89 | SCN10A (0.66) | SCN10ASCN2AKDM1AHDAC1MCHR1 | |
| SCHEMBL23327661 | 0.88 | SCN10A (0.57) | SCN10ASCN2AKDM1AHDAC1MCHR1 | |
| SCHEMBL23327995 | 0.87 | SCN10A (0.71) | SCN10ASCN2AKDM1AHDAC1MCHR1 | |
| SCHEMBL23328010 | 0.87 | SCN10A (0.57) | SCN10ASCN2AKDM1AHDAC1MCHR1 | |
| SCHEMBL23327655 | 0.86 | SCN10A (0.68) | SCN10ASCN2AKDM1AHDAC1 | |
| SCHEMBL23327988 | 0.86 | SCN10A (0.57) | SCN10ASCN2AKDM1AHDAC1MCHR1 | |
| SCHEMBL23327992 | 0.86 | SCN10A (0.59) | SCN10ASCN2AKDM1AHDAC1MCHR1 | |
| SCHEMBL29195333 | 0.85 | SCN10A (0.56) | SCN10ASCN2AKDM1AHDAC1MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210139456-A1 | PYRIDAZINE COMPOUNDS FOR INHIBITING NAV1.8 | LIEBER INSTITUTE, INC | 2021-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210139456-A1 | PYRIDAZINE COMPOUNDS FOR INHIBITING NAV1.8 | SCN8A, SCN5A, SCN2A | SCN10A 8/4885SCN2A 3/4885KDM1A 3241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.